Inhalon Biopharma Advances Breakthrough Inhaled Antibody Treatment for RSV, Targets 2026 Human Trials Inhalon Biopharma, Inc., a clinical-stage company pioneering innovative treatments for acute respiratory infections (ARI), has announced a major milestone in the development of its first-in-class inhaled antibody…
Pfizer’s BRAFTOVI® Combo Boosts Survival in Phase 3 BREAKWATER Trial Pfizer Inc. (NYSE: PFE) has announced promising results from the Phase 3 BREAKWATER study of BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin)…
Bioscience B.V., a pioneering commercial-stage specialty pharmaceutical company dedicated to advancing life-changing medicines for rare disease patients across Europe, has announced the appointment of Abdelghani (Abdel) Omari as its first-ever Chief Financial Officer (CFO). This strategic milestone strengthens the company’s…
AliveDx has announced the receipt of IVDR-CE mark for its MosaiQ AiPlex® CTDplus multiplex assay, a significant advancement in the diagnosis and management of Systemic Autoimmune Rheumatic Diseases (SARDs). This multiplex assay enables a syndromic approach, streamlining laboratory workflow while…
Janssen-Cilag International NV, a subsidiary of Johnson & Johnson, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the Subcutaneous European Medicines Agency (EMA) has issued a positive recommendation for an extension of marketing authorization for…
Marquis Who’s Who Recognizes Gail L. Lamoureux, BS, for Excellence in Health Care Gail L. Lamoureux, BS, a dedicated and accomplished professional in the health care industry, has been honored with inclusion in Marquis Who’s Who. This Marquis prestigious recognition…
Vertex Pharmaceuticals Announces Landmark Reimbursement Agreement with NHS England, Expanding Access to CASGEVY® for Sickle Cell Disease Patients Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has revealed a significant milestone in the fight against sickle cell disease (SCD) with the announcement of…
TWYMEEG® Sales Performance and Forecast Update Poxel’s Partner Sumitomo Pharma Reports TWYMEEG® Sales for Q4 and FY 2024 in Japan A clinical-stage biopharmaceutical company dedicated to developing innovative treatments for chronic and serious diseases characterized by metabolic pathophysiology, including metabolic…
BrightHeart, a global leader in artificial intelligence (AI) solutions for obstetrics and pediatric cardiology, recently presented two groundbreaking studies at the Society for Maternal-Fetal Medicine (SMFM) 2025 Pregnancy Meeting, which took place in Aurora, Colorado, on January 30th. These presentations,…
KORU Medical Systems Announces Strategic Collaboration for Phase III Clinical Trial on Expanded Drug Indication for Rare Renal Disorder KORU Medical Systems (NASDAQ: KRMD), a prominent medical technology company focused on innovative, patient-centric large volume subcutaneous infusion solutions, has announced…
Veradigm Completes Strategic Alternatives Review and Announces Operational Assessment Veradigm® (OTCMKTS: MDRX), a prominent provider of healthcare data and technology solutions, has concluded its previously announced strategic alternatives review, aimed at maximizing stockholder value. The company’s Board of Directors (the…
TROPION-Lung12 Phase 3 Trial Begins to Evaluate DATROWAY® as Part of Adjuvant Treatment for High-Risk Early-Stage Non-Small Cell Lung Cancer Patients Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all…